10 Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial[J]. Ann Rheum Dis, 2008, 67(11): 1516-1523.
[2]
11 Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study[J]. Arthritis Rheum, 2008, 58(10): 2968-2980.
[3]
12 Kremer JM, Fleischmann RM, Halland A, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study[J]. Arthritis Rheum, 2008, 58(12): 4031.
1 Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2012, 64(5): 625-639.
3 Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis[J]. Cochrane Database Syst Rev, 2010 (7): CD008331.
[8]
4 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581.
[9]
5 Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis[J]. Drugs, 2013, 73(4): 341-356.
7 Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update[J]. Ann Rheum Dis, 2014, 73(3): 492-509.
[12]
8 Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results[J]. J Rheumatol, 2013, 40(2): 113-126.
[13]
9 Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial[J]. Lancet, 2008, 371(9617): 987-997.
